Dopamine depleters in the treatment of hyperkinetic movement disorders

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 18, 2016, Pages 2461-2470

  Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chorea; Deutetrabenazine; dopamine; Huntington disease; hyperkinetic movements; orphan drug; tardive dyskinesia; tetrabenazine; Tourette syndrome; valbenazine; vesicular monoamine transporter; VMAT2

Indexed keywords

DEUTETRABENAZINE; DOPAMINE; TETRABENAZINE; VALBENAZINE; VESICULAR MONOAMINE TRANSPORTER; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

CLINICAL STUDY; DRUG EFFECT; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; HUNTINGTON DISEASE; HYPERKINESIS; METABOLISM; MOVEMENT DISORDERS; TARDIVE DYSKINESIA; TICS; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MOVEMENT DISORDERS; RECEPTORS, DOPAMINE; TARDIVE DYSKINESIA; TETRABENAZINE; TICS; TREATMENT OUTCOME;

EID: 84999836222     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1258063     Document Type: Review

References (76)

1. Jankovic J., Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844–856.
2. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26:147–152.
3. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, Part 2:treatment of tardive dyskinesia. Drugs. 2016 May;76(7):779–787.•• Comprehensive review of therapeutic strategies in the treatment of tardive dyskinesia.
4. Waln O, Jankovic J. An update on tardive dyskinesia:from phenomenology totreatment. Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12;3. pii:tre-03-161-4138-1. doi:10.7916/D88P5Z71.
5. Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder:an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921–936.
6. Ankenman R, Salvatore MF. Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J Neuropsychiatry Clin Neurosci. Winter 2007;19(1):65–69.
7. Lawal HO, Krantz DE. SLC18:vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2–3):360–372.
8. Benarroch EE. Monoamine transporters:structure, regulation, and clinical implications. Neurology. 2013 Aug 20;81(8):761–768.
9. Vaht M, Kiive E, Veidebaum T, et al. A functional vesicular monoamine transporter 1 (VMAT1) gene variant is associated with affect and the prevalence of anxiety, affective, and alcohol use disorders in a longitudinal population-representative Birth Cohort Study. Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii:pyw013. doi:10.1093/ijnp/pyw013.
10. Markos SM, Failla MD, Ritter AC, et al. Genetic variation in the vesicular monoamine transporter:preliminary associations with cognitive outcomes after severe traumatic brain injury. J Head Trauma Rehabil. 2016. [Epub ahead of print].
11. Yang X, Xu P, Zhao Q, et al. Polymorphism in the vesicular monoamine transporter 2 gene decreases the risk of Parkinson’s disease in Han Chinese men. Parkinsons Dis. 2015;2015:903164.
12. Lizarraga LE, Cholanians AB, Phan AV, et al. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine. Toxicol Sci. 2015 Jan;143(1):209–219.
13. Rilstone JJ, Alkhater RE, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368:543–550.
14. Wijemanne S, Jankovic J. Dopa-responsive dystonia–clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul;11(7):414–424.
15. German CL, Baladi MG, McFadden LM, et al. Regulation of the dopamine and vesicular monoamine transporters:pharmacological targets and implications for disease. Pharmacol Rev. 2015 Oct;67(4):1005–1024.•• An excellent review of pharmacology of VMAT and vesicular transport mechanisms.
16. Marecos C, Ng J, Kurian MA. What is new for monoamine neurotransmitter disorders? J Inherit Metab Dis. 2014 Jul;37(4):619–626.
17. Jankovic J, Sherer T. The future of research in Parkinson disease. JAMA Neurol. 2014 Nov;71(11):1351–1352.
18. Hsiao IT, Weng YH, Hsieh CJ, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014 Jun;71(6):758–766.
19. Arena JE, Stoessl AJ. Optimizing diagnosis in Parkinson’s disease:radionuclide imaging. Parkinsonism Relat Disord. 2016 Jan;22(Suppl 1):S47–S51.
20. Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington’s disease. Expert Opin Orphan Drugs. 2013;1:423–436.
21. Belleau B, Burba J, Pindell M, et al. Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science. 1961 Jan 13;133(3446):102–104.
22. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11:1509–1523.
23. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15;22(2):193–197.
24. Shen V, Clarence-Smith K, Hunter C, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013 Oct;22:3.
25. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease:a randomized controlled trial. Neurology. 2006;66:366–372.•• Report of the pivotal trial of TBZ that led to the approval of the drug by FDA for the treatment of chorea associated with HD.
26. Xenazineusa.com/HCP/MOA.
27. Kenney C, Hunter C, Davidson A, et al. Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord. 2007 Jan;22(1):10–13.
28. Schwartz DE, Bruderer H, Rieder J, et al. Metabolic studies of tetrabenazine, a psychotropic drug in animals and man. Biochem Pharmacol. 1966;15:645–655.
29. Mehanna R, Hunter C, Davidson A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28:210–215.
30. Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10:2883–2896.
31. Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014 Jan;11(1):153–160.
32. Jankovic J, Roos RA. Chorea associated with Huntington’s disease:to treat or not to treat? Mov Disord. 2014 Sep 15;29(11):1414–1418.
33. Baizabal-Carvallo JF, Stocco A, Muscal E, et al. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013 Apr;28(4):543–547.
34. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease:an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurology. 2009;9:62.
35. Ferrara JM, Mostile G, Hunter C, et al. Effect of tetrabenazine on motor function in patients with Huntington disease. Neurol Ther. 2012;1:5.
36. Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease:a pilot open label study. Tremor Other Hyperkinet Mov (N Y). 2012;2. pii:tre-02-86-476-4. doi:10.7916/D8DN43SC.
37. Fekete R, Davidson A, Ondo WG, et al. Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord. 2012;18:896–898.
38. Reilmann R, Rumpf S, Beckmann H, et al. Huntington’s disease:objective assessment of posture–a link between motor and functional deficits. Mov Disord. 2012;27:555–559.
39. Dorsey R, Biglan K, Eberly S, et al. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease:results from the TETRA-HD study. PLoS Curr. 2011 Nov 13;3:RRN1283.
40. Dorsey ER, Brocht AF, Nichols PE, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2(4):509–515.
41. Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29:259–264.
42. Albin RL, Koeppe RA, Wernette K, et al. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72:1390–1396.
43. Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan;29(1):126–130.
44. Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013 Aug;74(8):e772–e780.
45. Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord. 2015 Sep 15;30(11):1566–1573.
46. Thenganatt MA, Jankovic J. Recent advances in understanding and managing Tourette syndrome. F1000Res. 2016 Feb 9;5. pii:F1000 Faculty Rev-152. doi:10.12688/f1000research.7424.1.•• Comprehensive review of the treatment of TS, including TBZ.
47. Kenney C, Hunter C, Mejia N, et al. Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol. 2007;5:9–13.
48. Benchoua A, Trioulier Y, Diguet E, et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet. 2008;17:1446–1456.
49. Wang H, Chen X, Li Y, et al. Tetrabenazine is neuroprotective in Huntington’s disease mice. Mol Neurodegener. 2010 Apr;26(5):18.
50. Lohr KM, Bernstein AI, Stout KA, et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977–9982.
51. Howland RH. Deuterated drugs. J Psychosoc Nurs Ment Health Serv. 2015 Sep;53(9):13–16.
52. Mullard A. Deuterated drugs draw heavier backing. Nat Rev Drug Discov. 2016 Apr;15(4):219–221.
53. Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology. 2013;80:P07.210.
54. Huntington Study Group. Frank S, Testa, Cm Stamler E, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease:a randomized clinical trial. JAMA. 2016 Jul 5; 316(1):40–50.•• Report of the pivotal trial of deutetrabenazine in the treatment of HD-related chorea.
55. Claassen DO, Stamler D, Sung V. Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD):updated Week 8 results for the switch cohort. Presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders; 2016 Jun 21; Berlin, Germany.
56. Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6. doi:10.7916/D8M32W3H.
57. Jeon S, Walkup JT, Woods DW, et al. Detecting a clinically meaningful change in tic severity in Tourette syndrome:a comparison of three methods. Contemp Clin Trials. 2013 Nov;36(2):414–420.
58. Anderson KE, Factor SA, Jimenez-Shahed J, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD):A randomized, double-blind, placebo-controlled, fixed-dose study of deutetrabenazine for the treatment of moderate to severe tardive dyskinesia (TD). Poster presented at the 29th US Psychiatric and Mental Health Congress; October 21–24, 2016; San Antonio, Texas. Poster 206.
59. Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737–742.
60. O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia:a randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681–1687.
61. Factor SA, Hauser RA, Siegert S, et al. KINECT 3:A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia. Presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders; 2016 Jun 21; Berlin, Germany.
62. http://www.prnewswire.com/news-releases/neurocrine-announces-successful-completion-of-phase-ib-t-force-study-of-vmat2-inhibitor-nbi-98854-in-adolescents-and-children-with-tourette-syndrome-300194060.html.
63. Chen S, Zhang XJ, Xie WJ, et al. A New VMAT-2 inhibitor NBI-641449 in the treatment of Huntington disease. CNS Neurosci Ther. 2015 Aug;21(8):662–671.
64. Jankovic J. Medical treatment of dystonia. Mov Disord. 2013 Jun 15;28(7):1001–1012.
65. Luciano AY, Jinnah HA, Pfeiffer RF, et al. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord. 2014 Dec;20(12):1423–1426.
66. Fasano A, Bove F, Lang AE. The treatment of dystonic tremor:a systematic review. J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):759–769.
67. Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome:tetrabenazine versus neuroleptic drugs. J Child Neurol. 2008 Apr;23(4):435–437.
68. Burke RE, Reches A, Traub MM, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol. 1985;17:200Y202.
69. LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol. 2013 May-Jun;36(3):92–93.
70. Citrome L. Breakthrough drugs for the interface between psychiatry and neurology. Int J Clin Pract. 2016;70(4):298–299.
71. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis:a new syndrome. Neurology. 1985 Mar;35(3):366–370.
72. Jankovic J, Caskey TC, Stout JT, et al. Lesch-Nyhan syndrome:a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May;23(5):466–469.
73. Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia:a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32:95–99.
74. Howell LL, Negus SS. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol. 2014;69:129–176.
75. Nickell JR, Siripurapu KB, Vartak A, et al. The vesicular monoamine transporter-2:an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71–106.
76. Kaur N, Kumar P, Jamwal S, et al. Tetrabenazine:spotlight on drug review. Ann Neurosci. 2016 Sep;23(3):176–185.